All News
Filter News
Found 243 articles
-
bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress
5/16/2019
Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT
-
bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress
5/2/2019
Company hosting Analyst Day on May 9, 2019 focused on research and commercial strategies
-
The “One and Done” Era for Orphan Drugs: Evaluate Predicts 12% Growth, Driven by New Technologies, but Benefits Go to Big Pharma
4/25/2019
Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019
-
Somerset, NJ-based CRO Catalent announced it is acquiring Baltimore-based Paragon BioServices for $1.2 billion.
-
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.
-
bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype
3/29/2019
First gene therapy recommended for approval in the EU for TDT
-
What Are Biopharma Leaders Focused on?
3/27/2019
Numerous top biopharma executives met recently in Manalapan, Florida for the R&D Leadership Summit. Although a wide range of topics were discussed, certain areas rose to the top as being of particular concern to industry leadership. Here’s a look at a few of those concerns. -
Brammer has about 600 staffers at its primary locations in Massachusetts and Florida. The company was projected to bring in $250 million in revenue this year.
-
AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia
3/25/2019
The European Medicines Agency Human Medicines Committee (CHMP) has approved a Conditional Marketing Authorisation in the European Union for Zynteglo™
-
bluebird bio Statement on European Regulatory Status of LentiGlobin™
3/25/2019
A third party press release was issued stating that the EMA issued an approval for the conditional Marketing Authorization Application for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia.
-
The manufacturing plant will produce lentiviral vector for its gene and cell therapies, including bb2121 and bb21217 for multiple myeloma and possibly LentiGlobin for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease.
-
bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina
3/22/2019
Gov. Cooper to cut ribbon on facility that will strengthen bluebird bio's capabilities to manufacture products for clinical development and commercial supply
-
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
-
Pharmaceutical Collaborations and Rare Diseases Drive the Drugs to Watch as New Blockbusters Are Forecast to Hit the Market in 2019
3/20/2019
New report from Clarivate Analytics identifies seven new drugs predicted to achieve annual sales of >$1 billion by 2023
-
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
-
bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress
2/21/2019
bluebird bio, Inc. reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.
-
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
-
“Think of it as an installment plan that’s then tied to how well the therapy works,” Mark Trusheim, strategic director of the MIT Center for Biomedical Innovation’s NEWDIGS program, told Business Insider. “This would be a car loan but you’ve still got to see if the car is going to work.”
-
For a moment, simply contemplate the possible price: $2.1 million for a drug. It’s not just any drug, however. Cambridge, Mass.-based bluebird bio’s LentiGlobin is a gene therapy being evaluated for transfusion-dependent ß-thalassemia.
-
Tuesday, January 8, was another busy day in San Francisco for the JP Morgan Healthcare Conference. One interesting sideline was the idea that the current government shutdown could complicate some deals.